OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...

Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...

Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...

Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for ...

Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...

Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...

Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...

Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...

Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial ...

Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...

For primary care physicians, the question is increasingly whether continuous glucose data could answer a clinically useful ...